Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OSCR Stock Forecast 2025-2026
$17.52
Current Price
$4.39B
Market Cap
Buy 2
Hold 2
Sell 2
Wall St Analyst Ratings
Distance to OSCR Price Targets
+59.8%
To High Target of $28.00
-8.7%
To Median Target of $16.00
-31.5%
To Low Target of $12.00
OSCR Price Momentum
+2.4%
1 Week Change
+45.6%
1 Month Change
-22.2%
1 Year Change
+30.4%
Year-to-Date Change
-26.4%
From 52W High of $23.79
+56.4%
From 52W Low of $11.20
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Oscar Health (OSCR) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on OSCR and similar high-potential opportunities.
Latest OSCR Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, OSCR has a neutral consensus with a median price target of $16.00 (ranging from $12.00 to $28.00). The overall analyst rating is Buy (6.0/10). Currently trading at $17.52, the median forecast implies a -8.7% downside. This outlook is supported by 2 Buy, 2 Hold, and 2 Sell ratings.
The most optimistic forecast comes from Jessica Tassan at Piper Sandler, projecting a 59.8% upside. Conversely, the most conservative target is provided by David Windley at Jefferies, suggesting a 31.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OSCR Analyst Ratings
2
Buy
2
Hold
2
Sell
OSCR Price Target Range
Low
$12.00
Average
$16.00
High
$28.00
Current: $17.52
Latest OSCR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OSCR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 13, 2025 | Wells Fargo | Stephen Baxter | Equal-Weight | Downgrade | $16.00 |
| Dec 10, 2024 | Jefferies | David Windley | Underperform | Initiates | $12.00 |
| Nov 6, 2024 | B of A Securities | Adam Ron | Underperform | Downgrade | $13.50 |
| Oct 7, 2024 | UBS | Jonathan Yong | Neutral | Initiates | $23.00 |
| Sep 10, 2024 | Piper Sandler | Jessica Tassan | Overweight | Reiterates | $28.00 |
| Aug 8, 2024 | Piper Sandler | Jessica Tassan | Overweight | Maintains | $28.00 |
| Jul 10, 2024 | Piper Sandler | Jessica Tassan | Overweight | Maintains | $25.00 |
| Jun 26, 2024 | Piper Sandler | Jessica Tassan | Overweight | Initiates | $25.00 |
| Jun 12, 2024 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $27.00 |
| May 30, 2024 | B of A Securities | Adam Ron | Neutral | Downgrade | $21.00 |
| May 30, 2024 | Baird | Michael Ha | Outperform | Initiates | $28.00 |
| May 20, 2024 | B of A Securities | Adam Ron | Buy | Maintains | $25.00 |
| May 9, 2024 | Goldman Sachs | Nathan Rich | Neutral | Maintains | $21.00 |
| May 9, 2024 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $24.00 |
| Mar 22, 2024 | Raymond James | John Ransom | Outperform | Initiates | $20.00 |
| Feb 15, 2024 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $20.00 |
| Feb 9, 2024 | Goldman Sachs | Nathan Rich | Neutral | Maintains | $16.00 |
| Feb 8, 2024 | B of A Securities | Buy | Maintains | $0.00 | |
| Nov 2, 2023 | B of A Securities | Adam Ron | Buy | Upgrade | $9.00 |
| Aug 30, 2023 | Morgan Stanley | Ricky Goldwasser | Equal-Weight | Maintains | $7.50 |
Oscar Health, Inc. (OSCR) Competitors
The following stocks are similar to Oscar Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Oscar Health, Inc. (OSCR) Financial Data
Oscar Health, Inc. has a market capitalization of $4.39B with a P/E ratio of 43.1x. The company generates $10.08B in trailing twelve-month revenue with a 1.2% profit margin.
Revenue growth is +42.2% quarter-over-quarter, while maintaining an operating margin of +9.8% and return on equity of +10.5%.
Valuation Metrics
Market Cap
$4.39B
Enterprise Value
$1.59B
P/E Ratio
43.1x
PEG Ratio
30.7x
Price/Sales
0.4x
Growth & Margins
Revenue Growth (YoY)
+42.2%
Gross Margin
N/A
Operating Margin
+9.8%
Net Margin
+1.2%
EPS Growth
+55.2%
Financial Health
Cash/Price Ratio
+67.0%
Current Ratio
0.9x
Debt/Equity
26.9x
ROE
+10.5%
ROA
+2.1%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Oscar Health, Inc. (OSCR) Business Model
About Oscar Health, Inc.
What They Do
Provides innovative health insurance products and services.
Business Model
Oscar Health generates revenue by offering a range of health insurance plans to individuals, families, and businesses. The company focuses on user-friendly, affordable options while enhancing the healthcare experience through technology, such as a mobile app and telemedicine services.
Additional Information
Founded in 2012 and headquartered in New York City, Oscar Health aims to simplify health insurance with data-driven solutions and personalized customer service. Its modern approach challenges traditional insurance models, positioning it as a significant player in the evolving healthcare industry.
Company Information
Sector
Healthcare
Industry
Healthcare Plans
Employees
2,400
CEO
Mr. Mark Thomas Bertolini
Country
United States
IPO Year
2021
Website
www.hioscar.comOscar Health, Inc. (OSCR) Latest News & Analysis
Latest News
Quick Summary
U.S. healthcare stocks face pressure from increasing regulatory challenges and rising costs, impacting their performance in the market.
Why It Matters
Rising regulatory challenges and costs in the healthcare sector can erode profit margins, impacting stock performance and overall investor sentiment in the industry.
Source: The Motley Fool
Market Sentiment:
Negative
Quick Summary
Oscar Health is rated as a Hold due to potential 2026 budget cuts affecting Medicaid and Medicare. Despite strong revenue growth, macroeconomic risks may impact future performance.
Why It Matters
Oscar Health's rating as a Hold reflects concerns over budget cuts to Medicaid and Medicare, which could hinder growth despite strong financials and revenue projections.
Source: Seeking Alpha
Market Sentiment:
Negative
Quick Summary
Oscar Health, Inc. reported Q1 revenue growth of 42%, improved cost control, and expanding membership. Analysts see over 41% upside potential in the next 12-18 months amid favorable market conditions.
Why It Matters
Oscar Health's strong Q1 results and growth potential amid competitor exits suggest a robust investment opportunity, with significant upside projected in valuation and profitability.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Oscar Health (OSCR) stock rose after Q1 earnings surpassed estimates. The company reaffirmed its full-year guidance for all metrics.
Why It Matters
Oscar Health's strong earnings beat and reaffirmed guidance indicate robust financial health, potentially boosting investor confidence and driving stock prices higher.
Source: Yahoo Finance
Market Sentiment:
Positive
Quick Summary
Oscar Health, Inc. (NYSE:OSCR) will hold its Q1 2025 earnings conference call on May 7, 2025, at 8:00 AM ET, featuring key executives and analysts from various firms.
Why It Matters
Oscar Health's Q1 2025 earnings call will provide insights into financial performance, strategic direction, and market positioning, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Oscar Health Announces Strong Financial Results for First Quarter 2025 And Reaffirms 2025 Guidance
10 days ago
Quick Summary
Oscar Health, Inc. (NYSE: OSCR) reported strong Q1 2025 financial results, with significant year-over-year growth in revenue and net income, and anticipates further margin expansion.
Why It Matters
Oscar Health's strong Q1 results signal robust growth and profitability, impacting investor confidence and potentially driving stock price appreciation.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About OSCR Stock
What is Oscar Health, Inc.'s (OSCR) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Oscar Health, Inc. (OSCR) has a median price target of $16.00. The highest price target is $28.00 and the lowest is $12.00.
Is OSCR stock a good investment in 2025?
According to current analyst ratings, OSCR has 2 Buy ratings, 2 Hold ratings, and 2 Sell ratings. The stock is currently trading at $17.52. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OSCR stock?
Wall Street analysts predict OSCR stock could reach $16.00 in the next 12 months. This represents a -8.7% decrease from the current price of $17.52. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Oscar Health, Inc.'s business model?
Oscar Health generates revenue by offering a range of health insurance plans to individuals, families, and businesses. The company focuses on user-friendly, affordable options while enhancing the healthcare experience through technology, such as a mobile app and telemedicine services.
What is the highest forecasted price for OSCR Oscar Health, Inc.?
The highest price target for OSCR is $28.00 from Jessica Tassan at Piper Sandler, which represents a 59.8% increase from the current price of $17.52.
What is the lowest forecasted price for OSCR Oscar Health, Inc.?
The lowest price target for OSCR is $12.00 from David Windley at Jefferies, which represents a -31.5% decrease from the current price of $17.52.
What is the overall OSCR consensus from analysts for Oscar Health, Inc.?
The overall analyst consensus for OSCR is neutral. Out of 13 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 2 as Sell, with a median price target of $16.00.
How accurate are OSCR stock price projections?
Stock price projections, including those for Oscar Health, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 18, 2025 12:53 AM UTC